Immunovant (IMVT) Return on Capital Employed (2019 - 2026)
Immunovant (IMVT) posted Return on Capital Employed of 29.55% for Q1 2026, down 8282.12% on a QoQ basis from 0.35% in Q4 2025, and down 11196.0% year-over-year from N/an in Q1 2025.
Immunovant (IMVT) Return on Capital Employed (2019 - 2026) Analysis & Trends
Immunovant's Return on Capital Employed history runs 8 years deep, the most recent figure standing at 29.55% for Q1 2026.
- Quarterly Return on Capital Employed fell 11196.0% year-over-year to 29.55% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 29.55% (down 11196.0% YoY) and the FY2026 annual result came in at 25.37%, up 438.0% from the prior year.
- Return on Capital Employed was 29.55% for Q1 2026 at Immunovant, down from 0.35% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 151.75% in Q4 2023 and bottomed at 41.8% in Q3 2022.
- A 5-year average of 39.0% and a median of 10.23% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed soared 17917 bps — and 2026, when it sank 11196 bps.
- Immunovant's Return on Capital Employed stood at 20.1% in 2022, then jumped by 855 bps to 151.75% in 2023, then plunged by 58 bps to 62.98% in 2024, then tumbled by 101 bps to 0.35% in 2025, then plunged by 8282 bps to 29.55% in 2026.
- Business Quant data shows IMVT's Return on Capital Employed at 29.55% in Q1 2026, 0.35% in Q4 2025, and 10.23% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Immunovant | 7.18 Bn | 7.18 Bn | - | -29.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.55% |
| Dec 31, 2025 | -0.35% |
| Sep 30, 2025 | 10.23% |
| Jun 30, 2025 | 39.20% |
| Mar 31, 2025 | 82.41% |
| Dec 31, 2024 | 62.98% |
| Sep 30, 2024 | 115.61% |
| Jun 30, 2024 | 131.86% |
| Mar 31, 2024 | 109.23% |
| Dec 31, 2023 | 151.75% |
| Sep 30, 2023 | 137.37% |
| Jun 30, 2023 | 2.55% |
| Mar 31, 2023 | -23.73% |
| Dec 31, 2022 | -20.10% |
| Sep 30, 2022 | -41.80% |
| Jun 30, 2022 | -34.80% |
| Mar 31, 2022 | -29.80% |
| Dec 31, 2021 | -24.25% |
| Sep 30, 2021 | -26.21% |
| Jun 30, 2021 | 5.14% |